Japan expects to approve Merck's COVID pill in December
First oral medication expected to work on omicron variant
Merck's pill molnupiravir has been shown in trials to reduce deaths and hospitalizations by 30% among mild to moderate cases of COVID-19.
TOKYO -- Japan plans to approve Merck's coronavirus pill for sale by the end of this month through an expedited process for priority drug candidates, the regulators said Friday.
The Japanese arm of the U.S. drugmaker, MSD, applied the same day to the health ministry to manufacture and market the oral medication, molnupiravir.
Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.
Celebrate our next chapterFind out more
Free access for everyone - Sep. 30